Sugi Predict

Sugi Predict / Compounds / SCHEMBL4366959

SCHEMBL4366959

SCHEMBL4366959

CN1CCCC1COc1cc(Nc2nc3cc(Oc4ccnc5ccccc45)ccc3[nH]2)ccc1C(F)(F)F

nearest known ligand 0.90

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 14/20 0.90
▸ LCK P06239 2/20 0.43
▸ TEK Q02763 2/20 0.43
▸ AURKA O14965 1/20 0.43
▸ AURKB Q96GD4 1/20 0.43
▸ UTS2R Q9UKP6 2/20 0.42
▸ CSF1R P07333 1/20 0.41
▸ IGF1R P08069 1/20 0.41
▸ MET P08581 1/20 0.41
▸ KIT P10721 1/20 0.41
▸ FGFR1 P11362 1/20 0.41
▸ SRC P12931 1/20 0.41
▸ FGFR2 P21802 1/20 0.41
▸ FGFR4 P22455 1/20 0.41
▸ FGFR3 P22607 1/20 0.41
▸ PDE10A Q9Y233 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13861960 1.00 KDR (0.90) KDRLCKTEKAURKAAURKB
SCHEMBL4371822 0.85 KDR (0.72) KDRLCKTEKUTS2RCSF1R
SCHEMBL13861964 0.85 KDR (0.72) KDRLCKTEKUTS2RCSF1R
SCHEMBL13862520 0.84 KDR (0.90) KDRLCKTEKCSF1RIGF1R
SCHEMBL4367719 0.84 KDR (0.90) KDRLCKTEKCSF1RIGF1R
SCHEMBL4366963 0.80 KDR (0.59) KDRTEKPDE10A
SCHEMBL4361168 0.79 KDR (0.90) KDRLCKTEKCSF1RIGF1R
SCHEMBL4361916 0.79 KDR (0.90) KDRLCKTEKCSF1RIGF1R
SCHEMBL4365349 0.76 KDR (0.52) KDRLCKTEKAURKAAURKB
SCHEMBL4362208 0.74 KDR (0.82) KDRLCKTEKCSF1RIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1638954-A1 FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS AMGEN INC. (US) 2006-03-29 — — EP claimed
US-20040209892-A1 Heterocyclic compounds and methods of use U.S. PATENT OPERATIONS 2004-10-21 — — US claimed
WO-2004085425-A1 FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS AMGEN INC (US) 2004-10-07 — — WO claimed
US-7531553-B2 Heterocyclic compounds and methods of use AMGEN INC. (US) 2009-05-12 — — US disclosed
EP-1638954-A1 FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS AMGEN INC. (US) 2006-03-29 — — EP disclosed
US-20040209892-A1 Heterocyclic compounds and methods of use U.S. PATENT OPERATIONS 2004-10-21 — — US disclosed
WO-2004085425-A1 FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS AMGEN INC (US) 2004-10-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209892-A1 Heterocyclic compounds and methods of use VHL, NQO1, HPGDS KDR 83/4885LCK 1957/4885TEK 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.